RusVisk - information for patients

Intra-articular injections of liquid endoprostheses are a relatively new method of treating arthrosis, which is successfully practiced in many European countries. Many drugs are manufactured there and imported to Russia, where they are sold at inflated import prices. Along with them, our country also produces its own liquid endoprostheses, which, according to objective indicators, are in no way inferior, and sometimes even better, than foreign ones. Let's look at this trend using the example of the drugs Noltrex, RusVisk and Gialripayer.

DESCRIPTION

RusVisk® is a sterile, pyrogen-free, elastic-viscous buffered physiological solution of sodium hyaluronate of non-animal origin (pH 7 – 7.5). Supplied in a single-use glass syringe, sterile and intended only for intra-articular administration RusVisk® is a medical product (viscoelastic synovial fluid endoprosthesis), registration certificate No. FSR 2010/07890.

PROPERTIES

Hyaluronic acid is a natural polysaccharide belonging to the class of glycosaminoglycans, which is part of all tissues of the body and is the most important structural element of synovial fluid. The viscoelastic properties of hyaluronic acid, which is part of the synovial fluid, provide lubrication and shock absorption of the articular surfaces. Synovial fluid in joints affected by osteoarthritis has lower viscosity and elasticity than in healthy joints. Hyaluronic acid, which is part of RusVisk® , has a high molecular weight (3.5 • 106 Da) and creates favorable conditions for local therapy of osteoarthritis. Intra-articular administration of RusVisk® restores the physiological and rheological properties of the synovial fluid of a joint affected by osteoarthritis. As a result, pain and discomfort are reduced and mobility in the joint is improved.

"Gialripayer"

The “Hyalripayer” line from the Russian manufacturer includes many products, mainly for cosmetic purposes – based on hyaluronic acid. Chondroreparant occupies a very modest position among the huge variety of bioreparants.

The drug is hyaluronic acid stabilized using a special technology with ascorbic acid, amino acid and other active components. The drug is used to treat pathologies of joints, periarticular tissues and even the peripheral nervous system. Its action is based on stimulating natural metabolism, as a result of which the properties of synovial fluid improve and the destruction of cartilage slows down.

Note!

Contraindications to the use of chondroreparant include crystal deposition diseases, taking anticoagulants or coagulopathy. It is also prohibited for autoimmune connective tissue diseases.

"Hyalripayer" chondroreparant is recommended for use during extreme physical activity

CONTRAINDICATIONS

RusVisk® should not be used in the following cases:

Patients with hypersensitivity to one of the components of the composition.
Patients taking anticoagulants.
Patients with severe inflammation or infection of the joint, as well as intra-articular effusion.
Patients with signs of active skin disease or skin infection at the injection site or in the immediate vicinity of the injection site.
Pregnant women, nursing mothers and children.

RusVisk® is intended for intra-articular administration only .

A little about the price

Russian liquid endoprostheses are often not inferior to imported ones in price, while demonstrating quite high efficiency in the treatment of coxarthrosis, gonarthrosis and arthrosis of other joints. The cost of the first two drugs discussed above (“Gialripayer” and “RusVisk”) is approximately the same; they act for approximately 6-12 months, after which they are eliminated from the body and require a second course.

Those who treat arthrosis with the help of “ Gialripayer” or “RusVisk ” need to undergo treatment 1-2 times a year - say, 3 times in 2 years. With the cost of one course on average 15 thousand rubles. total costs for two years will be 45 thousand rubles. – 22-23 thousand rubles each. for a year . This figure may change in one direction or the other by about 5 thousand rubles, but, one way or another, treatment of arthrosis will cost at least 15 thousand rubles. in a year .

Noltrex is chosen as a liquid endoprosthesis , you will need to undergo a course of treatment once a year, every one and a half or two years. In the most difficult cases, when 4 injections are needed, which does not happen so often, the cost of the course will be 12,500 rubles. This amount will be enough for a year, one and a half or even two years - depending on the condition of the joint, and if there are only two or three injections, then the investment will drop to 7-9 thousand rubles. in year .

SIDE EVENTS

Side effects may appear immediately or over time. These include:

Pain during the injection, as well as redness or swelling in the joint area.
Limitation of mobility in the joint.

These phenomena are short-term and disappear spontaneously. If these symptoms persist for more than one week, the patient should consult a doctor. In exceptional cases, septic arthritis may occur; this complication should be suspected when a local inflammatory reaction occurs, increased pain in the joint, or increased body temperature.

INTERACTIONS WITH DRUGS

The effectiveness and safety of using RusVisk® in combination with simultaneous intra-articular administration of drugs has not been studied.
Incompatibility has been noted between sodium hyaluronate and quaternary ammonium salts such as benzalkonium chloride. Therefore, under no circumstances should RusVisk® be allowed to come into contact with such drugs or with medical and surgical instruments treated with such drugs.
Since the possible interaction of RusVisk® with prostheses has not been studied, it is not recommended to inject RusVisk® into joints with prostheses.

APPLICATION

RusVisk® is intended for intra-articular injections, which must be performed by a doctor with special training in a room equipped for intra-articular administration of the drug in compliance with all aseptic rules. Administration into the intravascular or extra-articular space, as well as into the tissue of the synovium or joint capsule is unacceptable.

Before administering the drug, the patient should be familiarized with the indications for use, contraindications, interactions with drugs and possible side effects.
The syringe should be removed from the refrigerator at least 20 minutes before use.
Any intra-articular effusion should be removed before administering RusVisk® .
Thoroughly clean the injection area with an appropriate antiseptic.
Make sure the individual sterile packaging is intact, then carefully remove it to remove the syringe. Remove air from the syringe and inject the drug into the synovial cavity of the joint using a 21 Gauge Luer Lock needle.
The course of local therapy for gonarthrosis using RusVisk® is 3-5 injections with a week interval between each. Simultaneous injection into several joints is possible.

"Hyalrepayer" in numbers

"Gialripayer" has passed clinical trials. The results of a study of the drug for post-traumatic gonarthrosis among athletes are indicative. The course of treatment for osteoarthritis of the knee joint included 3 injections of 2 ml each with an interval of 2 weeks. Using a special scale, the patients’ subjective sensations and objective indicators of the condition of the joint were assessed. The examination was carried out before the start of therapy, before the third injection, 3 and 6 months after the end of the course.

After two injections, the support functions of the injured limb improved in all patients. After 6 months, the pain syndrome completely disappeared, stabilometric parameters became more stable, and proprioceptive function was restored. Biomechanical parameters also showed objective improvement.

The results of using “Hyalripayer” for other diagnoses (arthrosis and periarthrosis of the facet joints, pericoxarthrosis, perigonarthrosis, glenohumeral periarthritis, etc.) are less optimistic:

in 23% there was a significant improvement (almost complete relief of pain and restoration of joint function);
in 66.7% – moderate improvement (significant reduction in pain, improvement in function, which requires continued therapy);
2.6% of cases had a questionable result (pain returned a week later to the starting point);
in 7.6% of cases there was no effect.

The drug is indicated for the purpose of blocking pain in diseases of the musculoskeletal system of intra-articular and extra-articular localization. The main condition is the absence of obvious manifestations of the inflammatory process.

"Hyalripayer" chondroreparant has a wide range of indications, in addition to arthrosis

DELIVERY FORM

RusVisk® comes in two forms: a box with 1 or 3 glass syringes with a Luer tip. Each syringe in the package comes with one or two sterile 21G2″ needles. The boxes are equipped with standard accessories: an annotation and a set of self-adhesive labels, which indicate the batch number to ensure control and subsequent medical monitoring of the patient. The contents of the syringe are sterile. The number of syringes in the package and the volume of substance in each syringe are indicated on the outer packaging.

"RUSVISK" Viscoelastic endoprosthesis of synovial fluid in a syringe 5 ml

Description of the RUSVISK endoprosthesis

Properties of the RUSVISK endoprosthesis

Rusvisk endoprosthesis of synovial fluid in a syringe 5 ml - indications

Pain and limitation of mobility due to degenerative-dystrophic and traumatic changes in the hip, knee and other synovial joints. RusVisk® is used for local therapy of stage I – III osteoarthritis. RusVisk® is used to temporarily replace synovial fluid or in addition to it.

Rusvisk endoprosthesis of synovial fluid in a syringe 5 ml - contraindications

RusVisk® should not be used in the following cases:

Patients with hypersensitivity to one of the components of the composition.
Patients taking anticoagulants.
Patients with severe inflammation or infection of the joint, as well as intra-articular effusion.
Patients with signs of active skin disease or skin infection at the injection site or in the immediate vicinity of the injection site.
Pregnant women, nursing mothers and children.

RusVisk® is intended for intra-articular administration only .

Rusvisk endoprosthesis of synovial fluid in a syringe 5 ml - side effects

Side effects may appear immediately or over time. These include:

Pain during the injection, as well as redness or swelling in the joint area.
Limitation of mobility in the joint.

INTERACTIONS WITH DRUGS

The effectiveness and safety of using RusVisk® in combination with simultaneous intra-articular administration of drugs has not been studied.
Incompatibility has been noted between sodium hyaluronate and quaternary ammonium salts such as benzalkonium chloride. Therefore, under no circumstances should RusVisk® be allowed to come into contact with such drugs or with medical and surgical instruments treated with such drugs.
Since the possible interaction of RusVisk® with prostheses has not been studied, it is not recommended to inject RusVisk® into joints with prostheses.

Rusvisk endoprosthesis of synovial fluid in a syringe 5 ml - application

Before administering the drug, the patient should be familiarized with the indications for use, contraindications, interactions with drugs and possible side effects.
The syringe should be removed from the refrigerator at least 20 minutes before use.
Any intra-articular effusion should be removed before administering RusVisk® .
Thoroughly clean the injection area with an appropriate antiseptic.
Make sure the individual sterile packaging is intact, then carefully remove it to remove the syringe. Remove air from the syringe and inject the drug into the synovial cavity of the joint using a 21 Gauge Luer Lock needle.
The course of local therapy for gonarthrosis using RusVisk® is 3-5 injections with a week interval between each. Simultaneous injection into several joints is possible.

Rusvisk endoprosthesis of synovial fluid in a syringe 5 ml - precautions

Intravascular administration of RusVisk® is unacceptable.
Carry out the injection strictly following the rules of asepsis.
Do not re-sterilize: syringes are disposable.
Before use, check the integrity of the outer sterile packaging: do not use the drug if the sterile packaging is damaged.
Do not use after expiration date.

Rusvisk endoprosthesis of synovial fluid in a syringe 5 ml - delivery form

Rusvisk endoprosthesis of synovial fluid in a syringe 5 ml - storage conditions

Store at temperatures between +5°C and +25°C.
Protect from sunlight.
Transportation is allowed at temperatures between +2°C and +25°C.
Do not freeze.

Attention: It is prohibited to use the material if the integrity of the packaging is violated! Categorically: Administration of the drug RusVisk® should be carried out only by a doctor in a medical institution, in a room equipped for intra-articular administration of drugs.

STORAGE CONDITIONS

Store at temperatures between +5°C and +25°C.
Protect from sunlight.
Transportation is allowed at temperatures between +2°C and +25°C.
Do not freeze.

is not responsible for the consequences of improper use of the drug RusVisk® .

Production: Rusvisk LLC, Russia, 117105, Moscow, st. Nagatinskaya, 3a.